Mark T. Iwicki
CHIEF EXECUTIVE OFFICER at KALA BIO Inc.
Sits on 4 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 12 years
- Director since
- 2023
12 years of board service in total across 4 boards, counting each seat separately. Longest: KALA BIO Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
KALA BIO Inc. January 30, 202697.0%
-
Jade Biosciences Inc. April 16, 202571.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 23, 2025 | KALA BIO Inc. | Open-market sale | −154,894 | $0.81 | $125,464 |
| Jun 24, 2025 | KALA BIO Inc. | Open-market sale | −13,227 | $4.01 | $53,040 |
| Jun 15, 2025 | KALA BIO Inc. | Grant or award | +2,450 | — | — |
| Jun 3, 2025 | KALA BIO Inc. | Open-market sale | +10,866 | $3.74 | $40,639 |
| Jan 6, 2025 | KALA BIO Inc. | Grant or award | +22,100 | — | — |
| Jan 6, 2025 | KALA BIO Inc. | Open-market sale | −5,779 | $7.63 | $44,094 |
| Jun 26, 2024 | KALA BIO Inc. | Open-market sale | −15,168 | $4.75 | $72,048 |
| May 31, 2024 | KALA BIO Inc. | Open-market sale | −7,392 | $6.09 | $45,017 |
| Jan 4, 2024 | KALA BIO Inc. | Grant or award | +14,300 | — | — |
| Jan 4, 2024 | KALA BIO Inc. | Open-market sale | −4,539 | $6.73 | $30,547 |
| Jun 22, 2023 | KALA BIO Inc. | Grant or award | +158,873 | — | — |
| May 31, 2023 | KALA BIO Inc. | Grant or award | +71,715 | — | — |
| Jan 4, 2023 | KALA BIO Inc. | Grant or award | +41,700 | — | — |
| Jan 4, 2023 | KALA BIO Inc. | Open-market sale | −198 | $28.54 | $5,651 |
Questions about Mark T. Iwicki
What boards is Mark T. Iwicki on?
Mark T. Iwicki sits on the boards of Inhibikase Therapeutics Inc., Jade Biosciences Inc., KALA BIO Inc. and Q32 Bio Inc.
What company is Mark T. Iwicki the CEO of?
Mark T. Iwicki has been Chief Executive Officer of Inhibikase Therapeutics Inc. since February 2025.
How long has Mark T. Iwicki served on boards?
Our records show at least 12 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.